NASDAQ:MRKR Marker Therapeutics Q1 2025 Earnings Report $1.23 -0.03 (-2.38%) Closing price 04/29/2025 04:00 PM EasternExtended Trading$1.24 +0.01 (+0.81%) As of 04/29/2025 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Marker Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.66Beat/MissN/AOne Year Ago EPSN/AMarker Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.50 millionBeat/MissN/AYoY Revenue GrowthN/AMarker Therapeutics Announcement DetailsQuarterQ1 2025Date5/21/2025TimeBefore Market OpensConference Call DateWednesday, May 14, 2025Conference Call Time7:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Marker Therapeutics Earnings HeadlinesMarker Therapeutics (MRKR) Receives a Buy from Canaccord GenuityApril 1, 2025 | markets.businessinsider.comMarker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology ConferenceApril 1, 2025 | markets.businessinsider.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. April 30, 2025 | Golden Portfolio (Ad)Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology ConferenceApril 1, 2025 | globenewswire.comMarker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last yearApril 1, 2025 | markets.businessinsider.comMarker Therapeutics Reports Year-End 2024 Corporate and Financial ResultsMarch 31, 2025 | globenewswire.comSee More Marker Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Marker Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Marker Therapeutics and other key companies, straight to your email. Email Address About Marker TherapeuticsMarker Therapeutics (NASDAQ:MRKR), a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.View Marker Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alphabet Rebounds After Strong Earnings and Buyback AnnouncementMarkets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryMarket Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial Earnings Upcoming Earnings Automatic Data Processing (4/30/2025)Equinix (4/30/2025)KLA (4/30/2025)Meta Platforms (4/30/2025)Microsoft (4/30/2025)QUALCOMM (4/30/2025)Aflac (4/30/2025)Allstate (4/30/2025)Caterpillar (4/30/2025)Canadian Pacific Kansas City (4/30/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
